In brief
- A systematic review compiles 12 clinical trials with a total of 174 participants who received salvinorin A, the active compound in Salvia divinorum.
- Effects arrive in seconds, peak within 1–2 minutes, and resolve in about 30 minutes when inhaled; the compound was found to be inactive when taken orally.
- No serious adverse events were reported, though the sample size is small and consists mostly of healthy volunteers with prior psychedelic experience.
There is plenty of talk about psilocybin and LSD, but Salvia divinorum is almost always relegated to a footnote. A Swiss team has just published the first systematic synthesis of what is known about its active principle, salvinorin A, administered to people in a research setting.
A psychedelic that bypasses serotonin
Salvinorin A is a pharmacological rarity. While psilocybin, LSD, and mescaline act on serotonin receptors, this molecule is a highly selective kappa-opioid receptor agonist. In other words, it produces an altered state of consciousness through a completely different pathway, which is why it is considered a useful model for studying how the experience changes when that system is activated.
In animals, the compound has shown promising effects in models of neuropsychiatric disorders. In humans, however, studies have been few, disparate, and scattered. Hence the value in organizing them.
What the authors found
The team, from the universities of Zurich and Bern, searched PubMed, Web of Science, and EMBASE through January 18, 2026. They included 12 clinical trials with 174 participants. Most were healthy volunteers who already had experience with hallucinogens, and almost all received the substance via inhalation, with doses ranging from 0.375 to 21 micrograms per kilogram (or 0.2 to 12 milligrams total).
The temporal profile is very different from that of classic psychedelics. Onset occurs in a matter of seconds, the peak arrives after one or two minutes, and everything resolves in about 30 minutes. Two studies tested the sublingual route: the onset was slower and the effect longer. In one, oral ingestion did nothing, which is consistent with the existing knowledge that the body degrades it before it can act.
Regarding safety, no serious adverse events were recorded. Physiological constants generally remained stable, with some mild increases in blood pressure or heart rate. On a psychological level, a portion of the participants described disorientation, anxiety, or discomfort during the experience, while others reported positive subjective changes. Long-term adverse effects were rare, and the abuse potential appeared low.
What it implies
These results should be read with the appropriate scale in mind. These are 174 people spread across twelve heterogeneous studies, under controlled conditions, with measured doses and pure substance. This does not equate to use outside the laboratory, where the dose, product, and context vary greatly, nor does it allow for conclusions regarding therapeutic effects: the review does not evaluate clinical efficacy. It also does not suggest that the subjective intensity of the experience is easy to manage; the study itself notes discomfort in some volunteers.
What it does provide is an honest map: a unique, fast-acting, and brief pharmacology, and an acceptable safety profile in a research context. The authors conclude that it justifies further cautious investigation in controlled studies. Those who want a general overview of the plant can consult our Salvia divinorum guide, and the general framework of harm reduction remains the reference for any informed decision.
Source
- Zürrer WE, Liesner J, Brüschweiler D, Aicher HD, Scheidegger M, Ineichen BV. Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety. Journal of Psychopharmacology, August 25, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
